Research Article

Symptoms of Intermittent Claudication and Decreased Walking Tolerance in Patients Suffering from Peripheral Arterial Disease can be Improved with a Simple Herbal Supplement

Yan Ping Yen Bryan, Woo Kam Sang, Kwok Chi Yui Timothy, Chook Ping and Leung Ping Chung

1Centre for Clinical Trials on Chinese Medicine, Institute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong
2State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong
3Division of Cardiology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
4Division of Geriatrics, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong

ABSTRACT

Introduction: We have developed an innovative herbal formula containing two herbs of popular use for the supplementation of cardiovascular health. Three clinical trials, viz. on patients with coronary arterial obstruction, hypertension, and post-menopausal borderline hyperlipidaemia, have been done, all showing promising results detected in ultrasonography as diminished intima media thickness (IMT), a surrogate marker recommended for clinical trials related to cardiovascular health. 49+49 patients with known peripheral arterial disease (PAD) were treated with twin formula or placebo group for 24 weeks. Assessment using ultrasonography showed thinning down of the carotid intimai (2.67%) only in the treatment group. Maximal walking distance also increased by 21.8% in the treatment group compared with 7.2% in the placebo group (p=0.499).

Discussion: The positive results in the PAD study as well as in the other studies done previously demonstrated the effectiveness of the twin formula in the maintenance of cardiovascular health. It is safe and offers direct protection of the internal environment of the artery while at the same time carries the multiple roles of anti-inflammation, anti-oxygenation and anti-fibrosis, as were shown in in vitro and animal bioactivity studies.

Conclusion and Outlook: The twin formula offers a good example of evidence-based medicinal supplements with specific functions. Its developmental process also offers a more comprehensive way to test traditional wisdom and practice through pragmatic clinical trials in the attempt to properly introduce it to modern health care practice.

© 2020 Leung Ping Chung. By Science Repository. All rights reserved.
related to cardiac symptoms, while *Puerariae* was a common household cooking material used this time as an innovative partner in the twin formula [4]. Whether the two herbs combined would have special cardiovascular supportive effects needs to be proven with basic bioscience experiments. Indeed, subsequently, series of platform studies have been completed to confirm many unique bioactivities of the twin formula: including its anti-inflammatory and anti-oxidative effects, vascular protection effects and vasculogenic potentials [5-11]. Subsequently, the twin formula was tested in two more clinical applications.

To evaluate the potential of the twin formula for primary atherosclerosis prevention in high-risk hypertensive patients, 90 patients (74.4% male) with hypertension associated with left ventricular hypertrophy (63.3%), diabetes mellitus (62.5%), and renal insufficiency (30%) were randomized to receive the twin formula or identical placebo capsules in a double-blind and parallel fashion for 12 months, on top of their anti-hypertensive treatments. Results showed that FMD and IMT improved significantly after the twin formula but not after the placebo treatment [12].

Later, a population-based sample of 165 postmenopausal women who experienced menopause for more than 12 months was recruited for the study of the preventive effects of the twin formula. These volunteers had border-line hyperlipidemia. Results showed that the carotid IMT decreased 1.52% from the baseline in the twin formula group (P < 0.004), but the decrease was only 1.13% for the placebo treatment group after a 12-month treatment [13].

**The Present Study**

The aging arterial system affects all vessels at various sites: from coronary to smaller vessels which affect blood pressure. Medium-sized arteries occur in the limbs, and in the lower limbs, if their patency is affected and blood flow becomes deficient, symptoms of “peripheral arterial disease” (PAD) become manifest. The prominent symptoms included intermittent claudications and diminished walking distances (limited by the painful symptoms and calf spasm). The peripheral arterial disease could be related to hypertension, and diabetes mellitus, making the situation more worrying. Progressive deteriorations of the arterial state lead to progressive distal ischaemia which might result in gangrene of the toes and possibly ending in amputations [14]. In view of the happy experience using the twin-herb formula in three clinical trials, the cardiologist designed a suitable protocol to make use of the twin formula to alleviate the symptoms of intermittent claudications in well-established cases of PAD.

**Methods**

**I Design of Clinical Trial**

A prospective, double-blind, placebo-controlled clinical trial lasting 24 weeks for 100 patients with known PAD was organized. The inclusion criteria were age above 40, suffering from intermittent claudications ranging from grade 1 to 3, and post-exercise ankle-brachial index <0.90. Selected patients did not experience any serious lower limb ischaemia, neither did they receive any vascular reconstructions.

**II Treatment**

98 patients were successfully recruited. 2 groups of 49 each were randomly assigned as treatment or placebo group. Production of the innovative twin formula was accomplished using best quality herbs grown in the acclaimed areas in China and subsequently made into 500 mg capsules in a laboratory of GMP standard. Placebo capsules were produced by the same laboratory strictly following the guidelines. Patients were given 3 capsules of the twin formula or placebo two times a day for a period of 24 weeks.

**III Assessment of Efficacy**

Apart from keeping a detailed pre- and post-treatment clinical record of standard symptoms and signs for PAD, two specific parameters were crucial for the assessment of efficacy. They were maximal walking distance (MWD) detected from treadmill walking (until claudication was experienced) and IMT of the carotid artery, a universally accepted surrogate marker for the arterial state. The intra-arterial state was assessed by measuring IMT.

**IV Statistical Analysis**

100 patients were recommended as the total number of clients basing on the assumption that improvement might reach an increased walking distance of 20 meters, SD 30, then reaching a 90% successful study. SPSS software was used to deal with the last observation carried forward (LOCF) problem. Paired t-tests would be suitable to compare the treatment and placebo groups, and P<0.05 would be considered statistically acceptable.

**Results**

**I Baseline Comparison between the Two Groups Confirmed They were of Comparable Nature**

Table 1: Some Basic Information Between the Two Groups.

| Patients | Twin Formula Group | Control Group | P Value |
|----------|-------------------|---------------|---------|
| Gender (M) | 34 (69.4) | 39 (79.6) | 0.247 |
| Smoker | 21 (42.9) | 22 (44.9) | 0.839 |
| DM | 26 (53.0) | 28 (57.1) | 0.685 |

**II MWD of the Two Groups Before and After Study**

Table 2: After 24-week treatment, the twin formula group MWD increased 21.8% compared with only 7.2% in the placebo group (P=0.499).

| Patients | Twin Formula Group | Control Group | P Value |
|----------|-------------------|---------------|---------|
| Age | 66.2±9.4 | 68.5±7.5 | 0.187 |
| Index (kg/m²) | 24.8±4.2 | 24.2±3.5 | 0.420 |
| Systolic BP | 144.7±16.9 | 150.5±21.5 | 0.142 |
| Diastolic BP | 71.9±10.4 | 73.6±11.9 | 0.460 |
| IMT (mm) | 1.159±0.624 | 1.083±0.343 | 0.456 |
As the human survival rate improves with advancing age, the incidence of PAD increases [14]. The progressive symptoms of intermittent claudication severely limit the activities of daily living of the PAD patients. While interventions to maintain the blood flow in the lower limbs of PAD patients are available and could be effective, many other cases might not be able to get the maximal benefits with the interventional procedures like stenting or bypass operations, since the obstruction could be extensive, multiple, or too distal [15]. Non-surgical means, if proven effective, will be a great help to such patients. As a matter of fact, PAD patients are often victims of multiple pathologies, showing a much higher incidence of coronary and cerebral involvement making active intervention even more difficult [16].

The twin formula consisting of herbs of common household use could be safely applied as an evidence-based specific supplement to improve vascular flow. As a matter of fact, narrowing down of the arterial lumen involves multiple pathological interactions, which include inflammation, smooth muscle spasm, platelet accumulations and intimal cellular metabolic malfunctions, etc. Mechanical correction applied as the major means of correction might work well in the short term only since the multiple pathological interactions still remain [16, 17]. In the situation of complete arterial block, the distal blood supply actually relies on multiple tributaries and collaterals. A sudden open up of the major block, e.g., in a stenting procedure, might even initiate a very much dreaded "no-flow phenomenon", leading to sudden complete distal ischaemia [18].

The twin formula has been studied extensively in the past 20 years and found to be able to effectively control inflammation, relax vascular smooth muscles and even help to lower circulating blood cholesterol. Its multiple dimensions of cardio- toxic effects would be beneficial to many different areas of arterial insufficiencies affecting a divergent variety of physiological activities: from coronary and cerebral function to more regional areas like PAD.

Conclusion and Outlook

Plant-based medicine has made tremendous historical contributions among ethnic groups, towards their general and special needs. Traditional Chinese medicine can be considered a huge system of therapy that particularly emphasizes on herbal treatment and supplements. Today we consider such practice as “Herbal Pharma therapy and Food: as complex interventions to support conventional treatment [19]. Most claims on food supplements are not based on strict pharmacological approaches but or epidemiological, histological observations, or in-vitro platform studies [20]. In spite of the lack of perfect justification, herbal supplements still enjoy advancing popularity [21]. One reason is related to the overutilization of costly treatment that might not be able to produce the expected quality of care. If supportive therapy like plant-based supplements can be proven to give effective specific supportive roles in standard treatment, it is going to occupy a unique position in the overall healthcare system, which currently appears to be underutilizing effective treatment [22].

In the past 18 years, we have been working on a research methodology that could possibly bring plant-based medicine closer to the effective treatment need. We identify areas of current need, which are often related to aging (like our presentation on cardiovascular health); then, we study classic records of herbal treatment to create an innovative formula (like the twin formula). Such a formula is strongly related to ethnopharmacology since it carries a strong traditional origin, and the herbs selected need to be assured of quality [20]. The formula is then put onto bioactivity platforms to investigate its effectiveness like anti-inflammatory, anti-oxidation, and in the case of PAD, specific properties related to cardiac health like blood lipids, vascular intima and flexibilities. When such in-vitro efficacies are proven, the formula could be put to proper clinical trials. The component herbs are well known and popular, hence, toxicity is not of major concern. The clinical trial protocol resembles one of the standard phase 2 to 3 level trials and the outcome of which gives sufficient evidence of effectiveness [11].

This paper describes the clinical results of the twin formula used to improve the symptoms of PAD. It serves as an example of how an evidence-based specific supplement could be developed. It is our belief...
that plant medicine offers not only phytochemical molecules for drug discovery but could be developed into effective treatment options in support of standard conventional therapy [23-25].

Ethical Approval

Proper approval from the regional ethics committee was obtained (2012.561-T).

Consent

All patients signed their consent forms.

Acknowledgements

This study was supported by Grants on State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants (The Chinese University of Hong Kong) from HKSAR and The Chinese University of Hong Kong.

Author Contributions

Leung Ping Chung: Responsible for the preparation of the manuscript.
Yan Ping Yen Bryan: Principle Investigator of the PAD trial. Woo Kam Sang: Principle Investigator of the Coronary trial. Kwok Chi Yui Timothy: Principle Investigator of the Menopausal Trial. Chook Ping: Took care of all the sonographic assessments.

Abbreviations

IMT: Intima Media Thickness
PAD: Peripheral Arterial Disease
FMD: Flow-mediated endothelium-dependent dilation
GMP: Good Manufacturing Practice
MWD: Maximal Walking Distance
LOCF: Last Observation Carried Forward

References

1. Chook P, Tam WY, Chan LT, Qiao M, ChengKF et al. (2011) Efficacy and Safety of Danshen and Gegen as adjunctive secondary prevention therapy in coronary arterial disease. S China J Cardiovasc Dis 17: 48-52.
2. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F et al. (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Branchial Artery Reactivity Task Force. J Am Coll Cardiol 39: 257-265. [Crossref]
3. Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J (2002) Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 20: 159-169. [Crossref]
4. Sun Y, Shaw PC, Fung KP (2007) Molecular authentication of Radix Puerariae Lobatae and Radix Puerariae Thomsonii by ITS and SS rRNA spacer sequencing. Biol Pharm Bull 30: 172-175. [Crossref]
5. Chiu PY, Leung HY, Leong PK, Chen N, Zhou L et al. (2012) Danshen-Gegen decoction protects against hypoxia/reoxygenation-induced apoptosis by inhibiting mitochondrial permeability transition via the redox-sensitive ERK/Nrf2 and PKC ε/nKATP pathways in H9c2 cardiomyocytes. Phytomedicine 19: 99-110. [Crossref]
6. Lam HM, Yam WS, Lau KM, Leung LK, Koon CM et al. (2005) Antioxidative and vasodilative effects of Danshen and Gegen. J Mol Cell Cardiol 38: 840.
7. Ng CF, Koon CM, Cheung DW, Lam MY, Leung PC et al. (2011) The anti-hypertensive effect of Danshen (Salvia miltiorrhiza) and Gegen (Pueraria lobata) formula in rats and its underlying mechanisms of vasorelaxation. J Ethnopharmacol 137: 1366-1372. [Crossref]
8. Chan YL, Woo KS, Leung PC, Fung KP (2006) Traditional Chinese medicine Danshen and Gegen combination formula improves Atherogenic pathophysiology: an in-vitro and ex-vivo study. J HK Coll Cardiol 14: 68.
9. Koon CM, Woo KS, Leung PC, Fung KP (2011) Salviae Miltiorrhizae Radix and Puerariae Lobatae Radix herbal formula mediates anti-atherosclerosis by modulating key atherogenic events both in vascular smooth muscle cells and endothelial cells. J Ethnopharmacol 138: 175-183. [Crossref]
10. Deng Y, Ng ES, Yeung JH, Kwan YW, Lau CB et al. (2012) Mechanisms of the cerebral vasodilator actions of isoflavonoids of Gegen on rat isolated basilar artery. J Ethnopharmacol 139: 294-304. [Crossref]
11. Leung PC, Koon CM, San Lau CB, Chook P, ChengKF et al. (2014) Development of an Effective Cardiovascular Protective Agent Using Evidence-based Research Platforms. Exp Clin Cardiol 20: 4235-4248.
12. Leung PC, Chook P, Fung KP, Woo KS (2010) Adjunctive Danshen and Gegen Therapy improves Atherogenic Process: A Final Report of Double-blind Placebo Control Trial in High Risk Hypertension. 23rd International society of Hypertension – meeting abstract 2010, Vancouver.
13. Kwok T, Leung PC, Lam C, Ho S, Wong CK et al. (2014) A randomized placebo controlled trial of an innovative Herbal Formula in the prevention of atherosclerosis in post-menopausal women. Complement Ther Med 22: 24-39. [Crossref]
14. Muluk SC, Muluk VS, Kelley ME, Whittle JC, Tierney JA et al. (2001) Outcome events in patients with claudication: a 15 year study in 2777 patients. J Vasc Surg 33: 251-257. [Crossref]
15. Woo KS, Chook P, Yu CW, Sung RY, Qiao M et al. (2004) Effects of diet and exercise on obesity related vascular dysfunction in children. Circulation 109: 1981-1986. [Crossref]
16. Marzilli M, Merz CN, Boden WE, Bonow RO, Capozza PG et al. (2012) Obstructive coronary atherosclerosis and ischaemic heart disease: an elusive link! J Am Coll Cardiol 60: 951-956. [Crossref]
17. Institute of Medicine (US) Committee on Preventing the Global Epidemic of Cardiovascular Disease (2010) Promoting cardiovascular health in the Developing World. National Academies Press (US). [Crossref]
18. Rezkalla SH, Kloner RA (2002) No-reflow phenomenon. Circulation 105: 656-662. [Crossref]
19. Witt CM (2013) Clinical research on traditional drugs and food items - the potential of comparative effectiveness research for interdisciplinary research. J Ethnopharmacol 147: 254-258. [Crossref]
20. Visoiu F (2012) Can experimental pharmacology be always applied to human nutrition? Int J Food Sci Nutr 63 Suppl 1: 10-13. [Crossref]
21. Greene SM, Reid RF, Larson EB (2012) Implementing the learning health system: from concept to action. Ann Intern Med 157: 207-210. [Crossref]
22. Friedly J, Bauer Z, Comstock B, DiMango E, Ferrara A et al. (2014) Challenges conducting comparative effectiveness research: the Clinical
and Health Outcomes Initiative in Comparative Effectiveness (CHOICE) Experience. *Comparat Effectiv Res* 2014: 1-12.

23. Sox HC, Greenfield S (2009) Comparative effectiveness research: report from the Institute of Medicine. *Ann Intern Med* 151: 203-205. [Crossref]

24. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S et al. (2009) Rethinking Randomized Clinical Trials for Comparative Effectiveness Research. The need for transformational change. *Ann Intern Med* 151: 206-210. [Crossref]

25. Tunis S, Stryer DB, Clancy CM (2003) Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. *JAMA* 290: 1624-1632. [Crossref]